Narrative review discusses CAR-T and HSC therapies for cancer and autoimmune conditions

This narrative review provides a broad overview of emerging cellular therapies, specifically focusing on chimeric antigen receptor T-cell (CAR-T), CAR-engineered regulatory T cell (CAR-Treg), and hematopoietic stem cell (HSC) applications. The scope of the discussion includes potential uses in cancer, Multiple Sclerosis, Type 1 Diabetes Mellitus, and other autoimmune diseases. No specific study population, sample size, or numerical outcomes are reported in this source.

The authors identify critical challenges that currently limit the widespread adoption of these advanced treatments. Key limitations noted include a heavy dependence on autologous cell sources, which can restrict availability. Additionally, the review points to high production costs and lengthy manufacturing timelines as substantial hurdles for clinical deployment. These factors contribute to the current restricted access for many patients who might benefit from these novel interventions.

The review does not report specific adverse events, tolerability data, or primary outcomes because it synthesizes existing literature rather than presenting new trial data. Consequently, the certainty of any specific efficacy claim is not quantified in this narrative format. The authors emphasize that the field requires continued research to overcome existing barriers.

Ultimately, the practice relevance of this review centers on the necessity for further investigation. Continued research is essential to facilitate the broader clinical implementation of these therapies across diverse healthcare settings. Until these logistical and economic challenges are addressed, the integration of CAR-T and HSC therapies into standard care will remain limited.